Sun Pharma Advanced Research Company Limited (NSE:SPARC) — Stock Price
Sun Pharma Advanced Research Company Limited (NSE:SPARC) is currently trading at Rs207.38 INR, down 2.73% today. Over the past 52 weeks, shares have ranged between Rs108.71 and Rs277.57. This page tracks Sun Pharma Advanced Research Company Limited's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Sun Pharma Advanced Research Company Lim stock valuation.
Sun Pharma Advanced Research Company Limited (SPARC) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Sun Pharma Advanced Research Company Limited's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Sun Pharma Advanced Research Company Limited Income Statement — Revenue, Profit & Earnings by Year
Sun Pharma Advanced Research Company Limited's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Rs717.70 Million | Rs755.45 Million | Rs2.39 Billion | Rs1.37 Billion | Rs2.53 Billion |
| Cost of Revenue | Rs231.20 Million | Rs1.99 Billion | Rs1.72 Billion | Rs1.27 Billion | Rs2.06 Billion |
| Gross Profit | Rs486.50 Million | Rs-1.24 Billion | Rs821.21 Million | Rs105.52 Million | Rs465.55 Million |
| Research & Development | Rs813.30 Million | Rs4.79 Billion | Rs4.53 Billion | Rs3.24 Billion | Rs3.88 Billion |
| SG&A | Rs917.20 Million | Rs1.52 Billion | Rs1.32 Billion | Rs695.23 Million | Rs519.34 Million |
| Total Operating Expenses | Rs3.27 Billion | Rs7.74 Billion | Rs3.06 Billion | Rs4.90 Billion | Rs1.92 Billion |
| Operating Income | Rs-2.78 Billion | Rs-4.12 Billion | Rs-2.24 Billion | Rs-1.97 Billion | Rs-1.46 Billion |
| EBITDA | Rs-3.23 Billion | Rs-3.73 Billion | Rs-2.03 Billion | Rs-1.80 Billion | Rs-1.30 Billion |
| EBIT | Rs-3.36 Billion | Rs-3.86 Billion | Rs-2.15 Billion | Rs-1.90 Billion | Rs-1.40 Billion |
| Interest Expense | Rs90.40 Million | Rs16.90 Million | Rs76.35 Million | Rs133.29 Million | Rs106.50 Million |
| Income Before Tax | Rs-3.43 Billion | Rs-3.87 Billion | Rs-2.23 Billion | Rs-2.03 Billion | Rs-1.51 Billion |
| Income Tax Expense | Rs-2.70 Million | Rs3.82 Million | Rs117.47 Million | Rs14.82 Million | Rs43.82 Million |
| Net Income | Rs-3.43 Billion | Rs-3.87 Billion | Rs-2.23 Billion | Rs-2.03 Billion | Rs-1.51 Billion |
Sun Pharma Advanced Research Company Limited Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Sun Pharma Advanced Research Company Limited's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Rs3.36 Billion | Rs5.15 Billion | Rs8.30 Billion | Rs2.80 Billion | Rs2.30 Billion |
| Total Current Assets | Rs261.90 Million | Rs2.69 Billion | Rs4.55 Billion | Rs711.52 Million | Rs631.11 Million |
| Cash & Equivalents | — | — | Rs1.11 Billion | — | — |
| Short-term Investments | Rs23.60 Million | Rs1.52 Billion | Rs4.02 Billion | Rs116.65 Million | Rs64.25 Million |
| Net Receivables | Rs160.60 Million | Rs184.03 Million | Rs374.18 Million | Rs309.25 Million | Rs176.44 Million |
| Inventory | Rs19.54 Million | Rs14.79 Million | Rs-41.68 Million | Rs-22.00K | Rs33.18 Million |
| Property, Plant & Equipment | Rs992.55 Million | Rs1.09 Billion | Rs1.07 Billion | Rs951.18 Million | Rs951.08 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Rs5.52 Billion | Rs3.89 Billion | Rs3.17 Billion | Rs2.49 Billion | Rs3.98 Billion |
| Total Current Liabilities | Rs3.74 Billion | Rs2.65 Billion | Rs1.79 Billion | Rs1.71 Billion | Rs2.33 Billion |
| Long-term Debt | Rs1.00 Billion | Rs0.00 | — | Rs0.00 | Rs1.17 Billion |
| Net Debt | Rs2.67 Billion | Rs558.22 Million | Rs150.90 Million | Rs779.89 Million | Rs2.27 Billion |
| Total Stockholder Equity | Rs-2.17 Billion | Rs1.26 Billion | Rs5.13 Billion | Rs312.26 Million | Rs-1.68 Billion |
| Retained Earnings | Rs-23.22 Billion | Rs-19.79 Billion | Rs-15.92 Billion | Rs-13.71 Billion | Rs-11.69 Billion |
Sun Pharma Advanced Research Company Limited Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Sun Pharma Advanced Research Company Limited generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs-3.60 Billion | Rs-4.29 Billion | Rs-691.20 Million | Rs-2.08 Billion | Rs-1.52 Billion |
| Capital Expenditures | Rs103.40 Million | Rs265.08 Million | Rs153.90 Million | Rs326.78 Million | Rs59.95 Million |
| Free Cash Flow | Rs-3.71 Billion | Rs-4.56 Billion | Rs-845.10 Million | Rs-2.41 Billion | Rs-1.58 Billion |
| Investing Cash Flow | Rs1.58 Billion | Rs3.92 Billion | Rs-5.48 Billion | Rs-291.67 Million | Rs15.62 Million |
| Financing Cash Flow | Rs1.99 Billion | Rs424.05 Million | Rs6.17 Billion | Rs2.29 Billion | Rs1.59 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Rs123.90 Million | Rs125.11 Million | Rs117.70 Million | Rs101.62 Million | Rs109.23 Million |
| Change in Cash | Rs-33.70 Million | Rs47.46 Million | Rs-6.40 Million | Rs-80.80 Million | Rs89.52 Million |
Sun Pharma Advanced Research Company Limited Earnings History — EPS Actual vs. Analyst Estimates
Track Sun Pharma Advanced Research Company Limited's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 18, 2026 | — | — | — |
| Feb 09, 2026 | — | — | — |
| Nov 03, 2025 | — | — | — |
| Aug 04, 2025 | — | — | — |
| Feb 10, 2025 | -2.45 | — | — |
| Nov 04, 2024 | -3.31 | 12.70 | -126.06% |
| Feb 05, 2024 | -3.07 | 10.00 | -130.70% |